These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 11035136)

  • 1. Pharmacokinetic, pharmacodynamic and clinical effects of a humanized IgG1 anti-CD4 monoclonal antibody in the peripheral blood and synovial fluid of rheumatoid arthritis patients.
    Choy EH; Connolly DJ; Rapson N; Jeal S; Brown JC; Kingsley GH; Panayi GS; Johnston JM
    Rheumatology (Oxford); 2000 Oct; 39(10):1139-46. PubMed ID: 11035136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial.
    Choy EH; Panayi GS; Emery P; Madden S; Breedveld FC; Kraan MC; Kalden JR; Rascu A; Brown JC; Rapson N; Johnston JM
    Rheumatology (Oxford); 2002 Oct; 41(10):1142-8. PubMed ID: 12364634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percentage of anti-CD4 monoclonal antibody-coated lymphocytes in the rheumatoid joint is associated with clinical improvement. Implications for the development of immunotherapeutic dosing regimens.
    Choy EH; Pitzalis C; Cauli A; Bijl JA; Schantz A; Woody J; Kingsley GH; Panayi GS
    Arthritis Rheum; 1996 Jan; 39(1):52-6. PubMed ID: 8546738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The elevated ratio of interferon gamma-/interleukin-4-positive T cells found in synovial fluid and synovial membrane of rheumatoid arthritis patients can be changed by interleukin-4 but not by interleukin-10 or transforming growth factor beta.
    Yin Z; Siegert S; Neure L; Grolms M; Liu L; Eggens U; Radbruch A; Braun J; Sieper J
    Rheumatology (Oxford); 1999 Nov; 38(11):1058-67. PubMed ID: 10556256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry.
    Berner B; Akça D; Jung T; Muller GA; Reuss-Borst MA
    J Rheumatol; 2000 May; 27(5):1128-35. PubMed ID: 10813277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD4(+)CD25(+) regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid.
    van Amelsfort JM; Jacobs KM; Bijlsma JW; Lafeber FP; Taams LS
    Arthritis Rheum; 2004 Sep; 50(9):2775-85. PubMed ID: 15457445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increase in adhesion molecules on CD4+ cells and CD4+ cell subsets in synovial fluid from patients with rheumatoid arthritis.
    Ueki Y; Eguchi K; Shimada H; Nakashima M; Ida H; Miyake S; Nagataki S; Tominaga Y
    J Rheumatol; 1994 Jun; 21(6):1003-10. PubMed ID: 7932407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of treatment with a fully human anti-tumour necrosis factor alpha monoclonal antibody on the local and systemic homeostasis of interleukin 1 and TNFalpha in patients with rheumatoid arthritis.
    Barrera P; Joosten LA; den Broeder AA; van de Putte LB; van Riel PL; van den Berg WB
    Ann Rheum Dis; 2001 Jul; 60(7):660-9. PubMed ID: 11406520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial.
    Choy EH; Isenberg DA; Garrood T; Farrow S; Ioannou Y; Bird H; Cheung N; Williams B; Hazleman B; Price R; Yoshizaki K; Nishimoto N; Kishimoto T; Panayi GS
    Arthritis Rheum; 2002 Dec; 46(12):3143-50. PubMed ID: 12483717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells.
    Ju JH; Heo YJ; Cho ML; Jhun JY; Park JS; Lee SY; Oh HJ; Moon SJ; Kwok SK; Park KS; Park SH; Kim HY
    Arthritis Rheum; 2012 Nov; 64(11):3543-52. PubMed ID: 22736176
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis.
    van Roon JA; Hartgring SA; Wenting-van Wijk M; Jacobs KM; Tak PP; Bijlsma JW; Lafeber FP
    Ann Rheum Dis; 2007 May; 66(5):664-9. PubMed ID: 17185327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proinflammatory mediator-induced reversal of CD4+,CD25+ regulatory T cell-mediated suppression in rheumatoid arthritis.
    van Amelsfort JM; van Roon JA; Noordegraaf M; Jacobs KM; Bijlsma JW; Lafeber FP; Taams LS
    Arthritis Rheum; 2007 Mar; 56(3):732-42. PubMed ID: 17328044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study.
    Baslund B; Tvede N; Danneskiold-Samsoe B; Larsson P; Panayi G; Petersen J; Petersen LJ; Beurskens FJ; Schuurman J; van de Winkel JG; Parren PW; Gracie JA; Jongbloed S; Liew FY; McInnes IB
    Arthritis Rheum; 2005 Sep; 52(9):2686-92. PubMed ID: 16142748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD4+ PD-1+ T cells accumulate as unique anergic cells in rheumatoid arthritis synovial fluid.
    Hatachi S; Iwai Y; Kawano S; Morinobu S; Kobayashi M; Koshiba M; Saura R; Kurosaka M; Honjo T; Kumagai S
    J Rheumatol; 2003 Jul; 30(7):1410-9. PubMed ID: 12858435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis.
    Morgan AW; Hale G; Rebello PR; Richards SJ; Gooi HC; Waldmann H; Emery P; Isaacs JD
    QJM; 2008 Apr; 101(4):299-306. PubMed ID: 18287112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose versus low dose fludarabine in the treatment of patients with severe refractory rheumatoid arthritis.
    Davis JC; Fessler BJ; Tassiulas IO; McInnes IB; Yarboro CH; Pillemer S; Wilder R; Fleisher TA; Klippel JH; Boumpas DT
    J Rheumatol; 1998 Sep; 25(9):1694-704. PubMed ID: 9733448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments.
    Scheerens H; Su Z; Irving B; Townsend MJ; Zheng Y; Stefanich E; Chindalore V; Bingham CO; Davis JC
    Arthritis Res Ther; 2011; 13(5):R177. PubMed ID: 22029963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of leukocyte and interleukin-1 beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate.
    Thomas R; Carroll GJ
    Arthritis Rheum; 1993 Sep; 36(9):1244-52. PubMed ID: 8216418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of two-dimensional gel electrophoresis to measure changes in synovial fluid proteins from patients with rheumatoid arthritis treated with antibody to CD4.
    Smith MA; Bains SK; Betts JC; Choy EH; Zanders ED
    Clin Diagn Lab Immunol; 2001 Jan; 8(1):105-11. PubMed ID: 11139202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The presence of cytokine-suppressive CD4+CD25+ T cells in the peripheral blood and synovial fluid of patients with rheumatoid arthritis.
    Liu MF; Wang CR; Fung LL; Lin LH; Tsai CN
    Scand J Immunol; 2005 Sep; 62(3):312-7. PubMed ID: 16179019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.